Lack of efficacy of tocilizumab in acute exacerbation of pulmonary fibrosis
<b>Given the high mortality rate observed in our data, tocilizumab is not recommended as a salvage therapy for patients affected by acute exacerbation of pulmonary fibrosis who did not show clinical improvement after three steroids bolus</b> https://bit.ly/3ClggYb.
Authors
- Camille Taillé (ORCID: https://orcid.org/0000-0001-9768-5728)
- Pierre Le Guen (ORCID: https://orcid.org/0000-0001-8608-4484)
- Giovanni Franco (ORCID: https://orcid.org/0000-0003-2873-5896)
- Clairelyne Dupin
- Quentin Philippot (ORCID: https://orcid.org/0000-0003-3429-9605)
- Catherine Bancal
- Bruno Crestani (ORCID: https://orcid.org/0000-0002-2961-3455)
- Raphaël Borie (ORCID: https://orcid.org/0000-0002-9906-0024)
- Marie‐Pierre Debray (ORCID: https://orcid.org/0000-0003-2109-5662)
- Mathilde Le Brun (ORCID: https://orcid.org/0009-0007-1906-453X)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1183/23120541.00520-2024
- Citations
- 2
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Institut National de la Santé et de la Recherche Médicale
- Assistance Publique - Hôpitaux de Paris
- Société de Pneumologie de Langue Française
- Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca